Conflicts of Interest in Drug Development: The Practices of Merck & Co., Inc.

Science and Engineering Ethics

Volumn 8, Issue 3, 2002, Pages 429-442

  Hirsch, Laurence J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bias; Clinical research; Conflict of interest; Data access; Drug development; Investigator; Pharmaceutical; Publication

Indexed keywords

BIOMEDICAL AND BEHAVIORAL RESEARCH; CHEMISTRY; CLINICAL TRIAL; CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS; HUMAN; MERCK INC.; PROFESSIONAL PRACTICE; REVIEW; STANDARD;

BIOMEDICAL AND BEHAVIORAL RESEARCH; MERCK INC.;

CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS; CONFLICT OF INTEREST; DRUG INDUSTRY; HUMANS; PROFESSIONAL AUTONOMY;

EID: 0036651641     PISSN: 13533452     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11948-002-0065-7     Document Type: Article

References (42)

1. Thompson, D.F. (1993) Understanding financial conflicts of interest. N Engl J Med 329: 573-576.
2. Smith, R. (1998) Beyond conflict of interest: transparency is the key. Br Med J 317: 291-292.
3. Cohen, J.J. (2001) Trust us to make a difference: ensuring public confidence in the integrity of clinical research. Acad Med 76: 209-214.
4. Horton, R. (1997) Conflicts of interest in clinical research: opprobrium or obsession? Lancet 349: 1112-1113.
5. Smith, R. (1994) Conflict of interest and the BMJ. Br Med J 308: 4-5.
6. Rennie, D. (1997) Thyroid storm. JAMA 277: 1238-1243.
7. 6/L CD4 cell counts. JAMA 284: 2193-2202.
8. Hrachovec, J.B., Mora, M., Wright, J.M., Perry, T.L., Bassett, K.L., Chambers, G. K., Silverstein, F., Simon, L., Faich, G. (2001) Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. JAMA 286: 2398-2400.
9. Loder, E. (2002) Sponsorship, authorship, and accountability (letter to the editor). N Engl J Med 346: 291.
10. Steneck, N.H. (2000) Assessing the integrity of publicly funded research - a background report for the November 2000 ORI Research Conference on Research Integrity. Accessed May 1, 2002, at http://www.ori.dhhs.gov/multimedia/acrobat/backg_int.pdf.
11. Weiss, R. B., Rifkin, R.M., Stewart, F.M., Theriault, R.L., Williams, L.A., Herman, A.A., Beveridge, R.A. (2000) High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet 355: 999-1003.
12. Angell, M., Kassirer, J.P. (1994) Setting the record straight in the breast-cancer trials. N Engl J. Med 330: 1448-1450.
13. Kohn, A. (1986) False prophets: fraud and error in science and medicine. The brilliant John Darsee. Blackwell, Oxford, England: 84-88.
14. DiMasi, J.A. (2001) Risks in drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 69: 297-307.
15. DiMasi, J. (2001) Tufts Center for the Study of Drug Development pegs cost of a new prescription medicine at $802 million. Press release Nov 30, 2001. Accessed May 15, 2002, at http://www.tufts.edu/med/csdd/Nov30CostStudyPressRelease.html.
16. Navia, M.A., Fitzgerald, P.M.D., McKeever, B.M., Leu, C.T., Heimbach, J.C., Herber, W.K., et al. (1989) Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 337: 615-620.
17. DeAngelis, C.D., Fontanarosa, P.B., Flanagin, A. (2001) Reporting financial conflicts of interest and relationships between investigators and research sponsors. JAMA 286: 89-91.
18. Davidoff, F., DeAngelis, C.D., Drazen, J.M., Hoey, J., Højgaard, L., Horton, R., et al. (2001) Sponsorship, authorship, and accountability. N Engl J Med 345: 825-827.
19. Lewis, S., Baird, P., Evans, R.G., Ghali, W.A., Wright, C.J., Gibson, E., Baylis, F. (2001) Dancing with the porcupine: rules for governing the university-industry relationship. CMAJ 165: 783-785.
20. Weintraub, W.S., Boccuzzi, S.B., Klein, J.L., Kosinski, A.S., King III, S.B., Ivanhoe, R., et al. for the Lovastatin Restenosis Trial Study Group. (1994) Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl JMed 331: 1331-1337.
21. Pitt, B., Poole-Wilson, P.A., Segal, R., Martinez, F.A., Dickstein, K., Camm, A.J., et al. for the ELITE II Investigators. (2000) Effect of losartan compared to captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587.
22. Topol, E.J., Moliterno D.J., Herrmann, H.C., Powers, E.R., Grines, C.L., Cohen, D.J. et al. for the TARGET Investigators. (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344: 1888-1894.
23. Navari, R.M., Reinhardt, R.R., Gralla, R.J., Kris, M.G., Hesketh, P.J., Khojasteh, A., et al. (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. N Engl J Med 340: 190-195.
24. Dickersin, K., Chan, S., Chalmers, T.C., (1987) Publication bias and clinical trials. Controlled Clin Trials 8: 343-353.
25. Easterbrook, P.J., Berlin, J.A., Gopalan, R., Matthews, D.R. (1991) Publication bias in clinical research. Lancet 337: 867-872.
26. Blumenthal, D., Campbell, E.G., Anderson, M.S., Causino, N., Louis, K.S. (1997) Withholding research results in academic life science: evidence from a national survey of faculty. JAMA 277: 1224-1228.
27. Davidson, R.A. (1986) Source of funding and outcome of clinical trials. J Gen Int Med 1: 155-158.
28. Stelfox, H.T., Chua, G., O'Rourke, K., Detsky, A.S. (1998) Conflict of interest in the debate over calcium-channel antagonists. N Engl J Med 338: 101-106.
29. Van Kolfschooten, F. (2002) Conflicts of interest: can you believe what you read? Nature 416: 360-363.
30. Rennie, D., Flanagin, A. (1994) Authorship! Authorship! Guests, ghosts, grafters and the two-sided coin. JAMA 271: 469-471.
31. Flanagin, A., Carey, L.A., Fontanarosa, P.B., Phillips, S.G., Pace, B.P., Lundberg, G.D., and Rennie, D. (1998) Prevalence of articles with honorary authors and ghost authors in peer-reviewed medical journals. JAMA 280:222-224.
32. The CONSENSUS Trial Study Group. (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435.
33. Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 344: 1383-1389.
34. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al for the FIT Research Group. (2000) Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 85: 4118-24. (Erratum J Clin Endocrinol Metab 2001 86: 938).
35. McConnell, J.D., Bruskewitz, R., Walsh, P., Andriole, G., Lieber, M., Holtgrewe, H.L., et al. for the Finasteride Long-Term Efficacy and Safety Study Group. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338: 557-563.
36. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., et al. For the AFCAPS/TexCAPS Research Group. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 279: 1615-1622.
37. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. for the VIGOR Study Group. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520-1528.
38. Brenner, B.M., Cooper, M.E., De Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H-H., et al. for the RENAAL Study Investigators. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869.
39. Dahlöf, B., Devereux, R.B., Kjeldsen, S., Julius, S., Beevers, G., de Faire, U., et al. for the LIFE Study Group. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995-1003.
40. Juni, P., Rutjes, A. W.S., Dieppe, P. A. (2002) Are selective COX-2 inhibitors superior to traditional nonsteroidal anti-inflammatory drugs? Adequate analysis of the CLASS trial indicates that this may not be the case (editorial). Br Med J 324: 1287-1288.
41. Drazen, J.M. and Curfman, G.D. (2002) Financial associations of authors (editorial). N Engl J Med 346: 1901-1902.
42. Smith, R. (2001) Maintaining the integrity of the scientific record - editors make a move (editorial). Br Med J 323: 588.